Women’s cancers still face a critical gap: we often lack early, scalable ways to predict which patient will benefit from a given therapy—leading to avoidable toxicity, delayed effective care, and expensive trial inefficiency. 4D Path Inc. has built QPOR™ (Q-Plasia OncoReader™), a physics-informed digital biology platform that generates interpretable, reproducible predictive biomarkers directly from routine H&E biopsy slides, without requiring extra tissue, sequencing, or specialized assays.QPOR computes patient-specific phenotypic measures of tumor/immune dynamics and cell-cycle deregulation from baseline biopsy images and returns structured, API-ready reports for clinical-trial enrichment and decision support workflows. We have demonstrated multi-study predictive performance, including blinded Phase II validation in breast cancer settings and a recent blinded biopharma validation in metastatic ovarian cancer. The platform is cloud-native and CPU-optimized for cost-efficient scale and integration into existing pathology and CRO workflows. It is supported by a robust patent portfolio (issued and pending) and has received FDA Breakthrough Device Designation in breast cancer, reinforcing a clear translational pathway toward clinical adoption.Core team: Tathagata Dasgupta, PhD (Founder/President/CTO) and Satabhisa Mukhopadhyay, PhD (Founder/CSO), supported by a world-class Scientific Advisory Board spanning oncology and pathology leadership—including KOLs from major academic cancer centers and global health organizations (e.g., senior leaders affiliated with Dana-Farber Cancer Institute, Yale Cancer Center, and the World Health Organization).